Statins inhibit Rho kinase activity in patients with atherosclerosis

Atherosclerosis

Volumn 205, Issue 2, 2009, Pages 517-521

  Nohria, Anju ^a   Prsic, Adnan ^a   Liu, Ping Yen ^b   Okamoto, Ryuji ^a   Creager, Mark A ^a   Selwyn, Andrew ^a   Liao, James K ^a   Ganz, Peter ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Atherosclerosis; Lipids; Rho kinase; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RHO KINASE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENZYME INHIBITION; FEMALE; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLACEBOS; PYRROLES; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 67650902217     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.12.023     Document Type: Article

References (27)

1. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 (1990) 425-430
2. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
3. Amano M., Fukata Y., and Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 261 (2000) 44-51
4. Laufs U., Endres M., Stagliano N., et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest 106 (2000) 15-24
5. Nohria A., Grunert M.E., Rikitake Y., et al. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 99 (2006) 1426-1432
6. Liu P.Y., Chen J.H., Lin L.J., and Liao J.K. Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol 49 (2007) 1619-1624
7. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
8. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
9. Stroes E.S., Koomans H.A., de Bruin T.W., and Rabelink T.J. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 346 (1995) 467-471
10. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
11. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
12. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
13. Ridker P.M., Danielson E., Fonseca F.A.H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
14. Landmesser U., Bahlmann F., Mueller M., et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111 (2005) 2356-2363
15. Piorkowski M., Fischer S., Stellbaum C., et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?. J Am Coll Cardiol 49 (2007) 1035-1042
16. Laufs U., and Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273 (1998) 24266-24271
17. Seasholtz T.M., Majumdar M., Kaplan D.D., and Brown J.H. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 84 (1999) 1186-1193
18. Miyata K., Shimokawa H., Kandabashi T., et al. Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol 20 (2000) 2351-2358
19. Ito T., Ikeda U., Shimpo M., et al. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc Drugs Ther 16 (2002) 121-126
20. Rikitake Y., and Liao J.K. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 111 (2005) 3261-3268
21. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
22. Laufs U., Marra D., Node K., and Liao J.K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 274 (1999) 21926-21931
23. Bourcier T., and Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 20 (2000) 556-562
24. Essler M., Retzer M., Bauer M., et al. Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase. J Biol Chem 274 (1999) 30361-30364
25. Libby P., and Ridker P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116 Suppl. 6A (2004) 9S-16S
26. Noma K., Rikitake Y., Oyama N., et al. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest 118 (2008) 1632-1644
27. Wang H.W., Liu P.Y., Oyama N., et al. Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice. FASEB J 22 (2008) 3561-3570